Sorrento gets US FDA nod for Phase 1 clinical trial of neutralising antibody in COVID-19 patients EP News Bureau Sep 17, 2020 Sorrento had earlier informed that COVI-GUARD (STI-1499) demonstrated 100 per cent in vitro neutralizing effect against SARS-CoV-2…
